The Psychiatry Consortium is a strategic collaboration of leading medical research charities and pharmaceutical companies to accelerate innovative drug discovery in psychiatric diseases.
The Psychiatry Consortium focuses on the challenge of identifying and validating novel drug targets to address the unmet therapeutic needs of the people living with mental health conditions.
Our first call for proposals is now open to applicants from academic institutions and other research institutes worldwide. Closing date 22nd November 2019 (23:59 GMT). Please download our Terms and Conditions and register to apply.
We’ve put together some Frequently Asked Questions to give you some more information on the types of projects that are in scope, how the application process works and to explain our Terms and Conditions further.
If you have a question that you can’t find the answer to, contact us at email@example.com.
The Psychiatry Consortium is seeking project proposals which focus on novel molecular drug-targets for the following mental health conditions:
- psychotic disorders, bipolar disorder, depression, anxiety, stress-related disorders, PTSD, OCD, autism spectrum disorders as well as psychiatric symptoms associated with dementia and other cognitive disorders
The Psychiatry Consortium intend to fund projects which:
- show some evidence that links the molecular target to human disease and of the target modulation having a therapeutic effect, which can be further developed or validated
- will enable tools for target validation e.g. through optimisation of existing tool compounds to improve selectivity, potency, bioavailability
Projects seeking to identify target modulation biomarkers relevant to disease will also be in scope.
What we will NOT fund
- projects focused on well-studied targets and pathways for psychiatry diseases
- projects with advanced chemistry e.g. lead/candidate molecules already synthesised and requiring only in vivo PK studies, preclinical proof-of-concept studies or IND-enabling studies
- non-pharmacological interventions
- purely academic explorations of new animal or cellular models (unless there is a clear drug discovery application, e.g. using the model as a tool for validating a new target)
- repurposing of existing drugs (unless as a method for validating new molecular targets)
- clinical trials
What we will offer
The Psychiatry Consortium will provide the successful applicants access to:
- drug-discovery expertise
- drug-discovery capabilities, through specialised Contract Research Organisation (CRO) partners
- commercial know-how
- project management resources
- project funding